LEDERMAN SETH (Chief Executive Officer) purchased 33.3% of their position (5K shares) of TONIX PHARMACEUTICALS HOLDING CORP. on the open market
Open‑market purchase worth $63.1K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 4/1/2026ACC: 0001999371-26-007447
DirectorOfficer· Chief Executive Officer
Since Jun 2018
+5K
Net shares
Net buyer
$63.1K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
5K acquired
Non-Derivative Transactions1
Common Stock, $0.001 par value
Indirect
Shares
+5K
Price / share
$12.62
Trade value
$63.10K
% of position
33.3%
3/31/2026
15K→20K
Total
Net shares
+5K
Net value
$63.10K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value Indirect | 3/31/2026 | P · Purchase | +5K | $12.62 | $63.10K | 33.3% | 15K | 20K |
| Total | +5K | $63.10K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock, $0.001 par value
DirectShares owned4K
Common Stock, $0.001 par value
IndirectShares owned1.00
Total
4K direct·1.00 indirect4.01K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock, $0.001 par value | 4K | Direct |
| Common Stock, $0.001 par value | 1.00 | Indirect |
| Total | 4.01K | 4K direct·1.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported